Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2007 by Monash University.
Recruitment status was  Active, not recruiting
Information provided by:
Monash University Identifier:
First received: February 9, 2006
Last updated: November 23, 2007
Last verified: November 2007

This study is designed to evaluate the efficacy and safety of oral DHEA 50mg daily, for 12 months in naturally menopausal women with low libido who are not receiving systemic oestrogen or oestrogen- progestin therapy.

Efficacy measures for the present study are effects on sexual function, wellbeing and menopausal symptoms. Safety measures will include endometrial assessment by transvaginal ultrasound (TVU), vital signs, lipid profiles, general electrolytes, effects on glucose metabolism and reports of adverse events.

Condition Intervention Phase
Decreased Libido
Quality of Life
Menopausal Symptoms
Drug: DHEA
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study to Evaluate the Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms

Resource links provided by NLM:

Further study details as provided by Monash University:

Primary Outcome Measures:
  • The primary objective is to assess the efficacy of oral DHEA therapy in postmenopausal women on sexual function [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • safety of DHEA treatment [ Time Frame: 12 months ]

Estimated Enrollment: 240
Study Start Date: February 2006
Estimated Study Completion Date: May 2008
Arms Assigned Interventions
Experimental: 1 Drug: DHEA
50 mg DHEA daily for 12 months
Placebo Comparator: 2 Drug: placebo
50 mg placebo for 12 months

  Show Detailed Description


Ages Eligible for Study:   40 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Women will be screened for study participation according to the following inclusion criteria at Visit 1 (Week -4). Generally healthy women must meet the following eligibility criteria:

  1. Be 40 to 65 years of age and at least 12 months postmenopausal (no spontaneous menses in the last 12 months, or be over the age of 55 years, or hysterectomy with one or both ovaries in situ and follicle-stimulating hormone [FSH] > 20 IU/L. (An FSH > 20 IU/L will also be used to confirm menopausal status in non-hysterectomised women < 55 years, where menopausal status is unclear.)
  2. Be sexually active - defined as being involved in any form of sexual activity at least once a month. Women do not require a partner.
  3. Body mass index (BMI) 18-34 kg/m2.
  4. Women will need to answer affirmatively to the following questions:

    • In previous years did you find sexual activity satisfying?
    • Do you feel that you have experienced a significant decrease in your desire or interest?
    • Would you like an improvement in your desire or interest for sexual activity?
    • Would you like to be treated for this?
  5. Have a clinically acceptable screening bilateral mammogram. Having documented normal results on a previous mammogram within 12 months prior to Week -4 is acceptable.
  6. Have ≤ 4 mm endometrial double thickness and no other abnormal findings on TVU if not hysterectomised.
  7. Have a clinically acceptable Pap smear (no evidence of malignancy or squamous intraepithelial lesions) if the cervix is present, within 12 months of Week -4; otherwise, a Pap smear will be done at Week -4.
  8. Be able and willing to participate in the study as evidenced by providing written informed consent.
  9. Baseline DHEAS level of < 2.1 umol/L (lowest 10th centile for women less than 45)

Exclusion Criteria:

  1. Have a BMI < 18 or > 34 kg/m2
  2. Dyspareunia not alleviated by use of lubricants.
  3. Severe depression (Beck Depression Inventory Score-II [BDI] > 20).
  4. Have partnership problems or poor feeling for partner. This will be established by interview by asking the following questions if a woman is in a specific relationship:

    1. Are you satisfied with your partner as a friend?
    2. Do you have concerns about your relationship?
  5. Have used recent androgen therapy (testosterone implant within the last 28 weeks, transdermal testosterone cream within the last 8 weeks, tibolone within the last 12 weeks, oral testosterone within the last 4 weeks and injected testosterone within the last 6 weeks).
  6. Have used treatment for depression (antidepressants, antipsychotics, antiepileptics) within 2 months prior to Week - 4 (Visit 1).
  7. Have known severe psychiatric illness.
  8. Have used estrogen, including vaginal conjugated equine estrogen, vaginal ring delivering up to 7.5 µg/day, or estrogen-progestin combinations in the last 2 months. (Use of Ovestin or Vagifem pessaries or cream will be allowed.)
  9. Used phytoestrogens within 1 week prior to Week -4 (Visit 1). (Women will be allowed to participate in this trial, provided they cease using phytoestrogens for at least 1 week before visit 1.)
  10. Have renal disease, liver disease, epilepsy or any other major illness that has occurred within the last 6 months.
  11. Therapies known to induce liver enzyme metabolism or alter the metabolism of DHEA e.g. antiepileptics, dexamethasone, or antituberculous drugs.
  12. Undiagnosed genital bleeding.
  13. Have moderate to severe acne or hirsutism, have used antiandrogen therapy for acne or hirsutism in the preceding 5 years, or have androgenic alopecia.
  14. Active malignancy or treatment for malignancy in the preceding 5 years (excluding non-melanotic skin cancer).
  15. Report alcohol consumption > 3 standard drinks per day.
  16. Have diabetes mellitus.
  17. Have a history of cerebrovascular disease, thromboembolic disorders, myocardial infarction or angina at anytime before study entry or thrombophlebitis within the last 5 years.
  18. An abnormal thyroid-stimulating hormone (TSH) value at screening (however, participants with an abnormal TSH, but normal free T4 and free T3 and no clinical signs or symptoms of thyroid disease, with or without replacement treatment, may be admitted to the study).
  19. Have abnormal liver function (LFTs) which, in the opinion of the investigator, is significant and/or an ALT or AST > 3 times the upper limit of normal or bilirubin > 2 times the upper limit of normal.
  20. Have, in the opinion of the investigator, any clinically significant pre-treatment laboratory parameter, which the investigator feels would impact on the health and well-being of the woman's ability to participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00289926

Australia, Victoria
Women's Health Program, Monash Medical School, The Alfred Hospital
Melbourne, Victoria, Australia, 3181
Sponsors and Collaborators
Monash University
Principal Investigator: Susan R Davis, MBBS, PhD Monash University
  More Information

Additional Information:
No publications provided Identifier: NCT00289926     History of Changes
Obsolete Identifiers: NCT00394342
Other Study ID Numbers: WHP 200501
Study First Received: February 9, 2006
Last Updated: November 23, 2007
Health Authority: Australia: National Health and Medical Research Council

Keywords provided by Monash University:
low libido
lack of wellbeing processed this record on November 24, 2014